Vertex announces new data on als-2200 in people with hepatitis c, supporting advancement into phase 2 all-oral studies in 2012; ends development of als-2158

Cambridge, mass.--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and its collaborator alios biopharma, inc. today announced results from a viral kinetic study of the adenosine nucleotide analogue pro-drug als-2158 for the treatment of hepatitis c. data showed that seven days of dosing with up to 900 mg of als-2158 was well-tolerated in people with genotype 1 chronic hepatitis c, but that there was insufficient antiviral activity to warrant proceeding with further clinical development. the companies also announced new data from an additional cohort of an ongoing viral kinetic study of the uridine nucleotide analogue pro-drug als-2200 in combination with ribavirin. there was a median 4.18 log10 reduction from baseline in hcv rna after seven days of dosing with a once-daily 200 mg dose of als-2200 in combination with ribavirin in people with genotype 1 chronic hepatitis c who were new to treatment (n=8). five patients achieved hcv rna levels below the limit of quantification (
VRTX Ratings Summary
VRTX Quant Ranking